Abstract
Abstract
The seasonal influenza vaccine remains one of the vital recommended infection control measures for healthy individuals and the elderly with chronic illnesses. Nonetheless, a universal vaccine, which can be administered once and offer long-term protection against influenza, still has a few steps to go before it becomes available to the general public. We investigated the immunogenicity of a single dose of influenza vaccine in 123 seronegative participants and classified them into four distinct groups, determined by the promptness of their vaccine response, the longevity of their humoral immunity, and the likelihood of exhibiting cross-reactivity. Subsequently, we used transcriptional profiling and differential gene expression analysis to identify potential genes directly associated with the robust response to the vaccine. Our findings point out a list of expressed proteins that are related to B cell proliferation, unfolded protein response and cellular hemostasis, as well as a linkage of these expressions to the survival of long-lived plasma cells.
Publisher
Research Square Platform LLC
Reference111 articles.
1. "Complications of viral influenza.";Rothberg MB;The American journal of medicine,2008
2. "Who and when to vaccinate against influenza;Buchy P;International Journal of Infectious Diseases,2020
3. The efficacy of influenza vaccine for healthy children. A meta-analysis evaluating potential sources of variation in efficacy estimates including study quality;Manzoli L;Pediatr Infect Dis J,2007
4. Vaccines for preventing influenza in health children;Jefferson T;Cochrane Database of Systematic Reviews,2008
5. Influenza vaccine in health children: a meta-analysis;Negri E;Vaccine,2005